The SAVITRI Study is evaluating the safety and effectiveness of a once-daily oral investigational medication on improving symptoms of MDD in patients who are having an inadequate response to antidepressant medication(s).

Who May Qualify

Eligible participants must:

• Be 18 to 65 years of age (inclusive)
• Have a confirmed diagnosis of MDD
• Be currently on antidepressant medication(s)
• Have had inadequate response to up to 5 oral antidepressant medications
• Not be pregnant or breastfeeding
• Not have a current psychiatric disorder other than MDD

Study Participation

The total length of the SAVITRI Study is approximately 14 weeks. This includes a 4-week screening period to make sure the research study is a good match for you, an 8-week treatment period in which you will receive 1 of 2 doses of the investigational medication or the placebo, and a 2-week follow-up period to check on your health after stopping the assigned study treatment. Participants in the SAVITRI Study will be able to stay on their current antidepressant medication(s) while in the research study.

Throughout the research study, your study doctor may perform a number of tests and procedures, including but not limited to:

• Recording your medical history
• Conducting a physical exam
• Measuring your vital signs
• Conducting a pregnancy test (if applicable)
• Collecting blood and urine samples